Invitae Corp
NYSE:NVTA
Invitae Corp
NYSE:NVTA
Price:
0.61 USD
Market Closed
Updated:
Oct 1, 2023
Section:
Relative Value
The Relative Value of one
NVTA
stock under the Base Case scenario is
8.27
USD.
Compared to the current market price of 0.61 USD,
Invitae Corp
is
Undervalued by 93%.
Relative valuation is one of two methods of placing a monetary value on a company; the other is Discounted Cash Flow valuation method. We use a combination of these two methods to calculate the Intrinsic Value of stock as accurately as possible.
Relative Valuation FAQ:
NVTA
Relative Value
Base Case
8.27
USD
Undervaluation 93%
Multiples Across Competitors
NVTA Competitors Multiples
Invitae Corp Competitors
Invitae Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Invitae Corp
NYSE:NVTA
|
163m USD | 0.3 | -0.1 | -2.3 | -1.8 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
89.7B USD | 0.3 | 30.7 | 9 | 9 | |
| US |
|
Cigna Corp
NYSE:CI
|
84.7B USD | 0.5 | 12.7 | 8 | 10.5 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
17.9B USD | 1.3 | 21.6 | 10.1 | 14.1 | |
| DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
16.6B EUR | 0.4 | 16.6 | 6.5 | 13.2 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
13.6B USD | 1.4 | 17.3 | 10.1 | 13.6 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
12B EUR | 0.6 | 17.8 | 6.6 | 14.4 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | 4.4 | -18.6 | -23.3 | -21.5 | |
| AU |
|
Sonic Healthcare Ltd
ASX:SHL
|
14B AUD | 1.7 | 20.5 | 15.7 | 15.7 | |
| US |
|
DaVita Inc
NYSE:DVA
|
8.7B USD | 0.7 | 18.6 | 8.4 | 13.5 | |
| US |
|
Chemed Corp
NYSE:CHE
|
7.8B USD | 3.6 | 34.4 | 20.3 | 24.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
